Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Reparixin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 known ✓ | P25025 | 6/20 | 1.00 |
| ▸ | CXCR1 known ✓ | P25024 | 5/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.67 |
| ▸ | PDE4A | P27815 | 1/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.58 |
| ▸ | ALB | P02768 | 1/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.58 |
| ▸ | RARB | P10826 | 1/20 | 0.58 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.58 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.58 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Reparixin SCHEMBL1884300 | 1.00 | CXCR2 (1.00) | CXCR2CXCR1THRBCHRM1PDE4A | |
| SCHEMBL13802357 | 0.87 | CXCR2 (0.76) | CXCR2CXCR1THRBCHRM1PDE4A | |
| SCHEMBL13802644 | 0.87 | CXCR2 (0.76) | CXCR2CXCR1THRBCHRM1PDE4A | |
| SCHEMBL13802533 | 0.87 | CXCR2 (0.76) | CXCR2CXCR1THRBCHRM1PDE4A | |
| SCHEMBL1082214 | 0.86 | CXCR1 (0.76) | CXCR2CXCR1THRBCHRM1PDE4A | |
| SCHEMBL27925055 | 0.85 | CXCR1 (0.74) | CXCR2CXCR1THRBCHRM1PDE4A | |
| Reparixin SCHEMBL29406454 | 0.82 | THRB (1.00) | CXCR2CXCR1THRBCHRM1PDE4A | |
| Reparixin SCHEMBL27192398 | 0.82 | THRB (1.00) | CXCR2CXCR1THRBCHRM1PDE4A | |
| Hydrochloric Acid SCHEMBL7776911 | 0.82 | CXCR1 (0.70) | CXCR2CXCR1THRBCHRM1PDE4A | |
| SCHEMBL27573450 | 0.81 | CXCR1 (0.68) | CXCR2CXCR1THRBCHRM1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 790 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099526-A1 | COMBINATION OF INHIBITORS OF IL-1BETA, CCR5 OR CXCR2 CYTOKINE RECEPTORS FOR USE IN THE TREATMENT OF METASTASIS | FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA (ES) | 2026-05-15 | — | — | WO | claimed |
| US-20260048030-A1 | REPARIXIN LIQUID SUSPENSIONS | DOMPE FARM SPA (IT) | 2026-02-19 | — | — | US | claimed |
| US-12553904-B2 | Methods of detecting and treating cerebral aneurysms | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2026-02-17 | — | — | US | claimed |
| EP-4686469-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF DIABETES-ASSOCIATED COMORBIDITIES | Dompé farmaceutici SpA (IT) | 2026-02-04 | — | — | EP | claimed |
| EP-4686472-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE | Dompé farmaceutici SpA (IT) | 2026-02-04 | — | — | EP | claimed |
| EP-4681707-A1 | METHOD FOR TREATING DISEASES BY USING REPARIXIN ALONE OR IN COMBINATION WITH ANTI-PD-1 ANTIBODY | Shandong Cancer Hospital Affiliated to Shandong First Medical University (CN) | 2026-01-21 | — | — | EP | claimed |
| US-20260014105-A1 | POWDER MIXTURE COMPRISING REPARIXIN | DOMPE FARM SPA (IT) | 2026-01-15 | — | — | US | claimed |
| EP-4678171-A1 | SYSTEMICALLY-ADMINISTERED CXCL8 INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | Dompé farmaceutici SpA (IT) | 2026-01-14 | — | — | EP | claimed |
| US-20250376522-A1 | Targeting Cells with a Combination of CXCR2 Inhibition and CD47 Blockade | UNIV LELAND STANFORD JUNIOR (US) | 2025-12-11 | — | — | US | claimed |
| US-20250347700-A1 | METHODS OF DETECTING AND TREATING CEREBRAL ANEURYSMS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-11-13 | — | — | US | claimed |
| WO-2018219865-A1 | IL-8 INHIBITORS FOR USE IN THE TREATMENT AND/OR PREVENTION OF BACTERIAL SECONDARY INFECTIONS | DOMPE' FARMACEUTICI S.P.A. (IT) | 2018-12-06 | — | — | WO | claimed |
| EP-3409277-A1 | IL-8 INHIBITORS FOR USE IN THE TREATMENT AND/OR PREVENTION OF BACTERIAL SECONDARY INFECTIONS | Dompé farmaceutici s.p.a. (IT) | 2018-12-05 | — | — | EP | claimed |
| EP-3402474-A1 | IL-8 INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY | Dompé farmaceutici S.p.A. (IT) | 2018-11-21 | — | — | EP | claimed |
| EP-3316886-A1 | METHODS AND COMPOUNDS FOR THE ALLEVIATION AND/OR PREVENTION OF PAIN | Svensson, Camilla (SE) | 2018-05-09 | — | — | EP | claimed |
| WO-2017121838-A1 | IL-8 INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY | DOMPE' FARMACEUTICI S.P.A. (IT) | 2017-07-20 | — | — | WO | claimed |
| EP-3192504-A1 | IL-8 INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY | Dompé farmaceutici S.p.A. (IT) | 2017-07-19 | — | — | EP | claimed |
| US-20170181987-A1 | INHIBITION OF IL-8 IN THE TREATMENT OF PAIN AND/OR BONE LOSS | SVENSSON CAMILLA (SE) | 2017-06-29 | — | — | US | claimed |
| US-20170165363-A1 | CANCER CELL MIGRATION INHIBITORS AND THEIR USE IN THERAPEUTIC TREATMENTS | THE JOHNS HOPKINS UNIVERSITY | 2017-06-15 | — | — | US | claimed |
| WO-2017007403-A1 | METHODS AND COMPOUNDS FOR THE ALLEVIATION AND/OR PREVENTION OF PAIN | SVENSSON CAMILLA (SE) | 2017-01-12 | — | — | WO | claimed |
| US-20150065575-A1 | S100A8/A9 as a Diagnostic Marker and a Therapeutic Target | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2015-03-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165363-A1 | CANCER CELL MIGRATION INHIBITORS AND THEIR USE IN THERAPEUTIC TREATMENTS | IL6, CXCL8, IL6ST | CXCR2 73/4885CXCR1 129/4885THRB 3426/4885 |
| US-12553904-B2 | Methods of detecting and treating cerebral aneurysms | NTRK2, NTRK3, CHI3L1 | CXCR2 110/4885CXCR1 263/4885THRB 331/4885 |
| US-20260014105-A1 | POWDER MIXTURE COMPRISING REPARIXIN | CROCC, RDX, MTX1 | CXCR2 293/4885CXCR1 299/4885THRB 4015/4885 |
| US-20260048030-A1 | REPARIXIN LIQUID SUSPENSIONS | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885CXCR1 2/4885THRB 3252/4885 |
| US-20250347700-A1 | METHODS OF DETECTING AND TREATING CEREBRAL ANEURYSMS | FABP7, S100B, VASP | CXCR2 3111/4885CXCR1 4315/4885THRB 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.